Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Clin Cancer Res · 2022 · PMC9377742 · PMID 34907082

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

On the other hand, although some AKT substrates showed a trend of elevation, the integrated AKT pathway score was not significantly higher in PIK3CA / AKT1 / PTEN -altered (NGS) or PTEN-low (IHC) tumors ( Fig. 2A and B ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The NGS/IHC biomarker negative, pAKT-high subgroup had a small sample size ( n = 17) and did not reach statistical significance despite the clear trend.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.